Vanguard Capital Management
PVLA

Vanguard Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Vanguard Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.5M Buy
513,794
+36,500
+8% +$4.43M ﹤0.01% 1691
2026
Q1 		$59.5M Buy
+477,294
New +$49.8M ﹤0.01% 1767

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management's PVLA Position: Q2 2026 in Review

Vanguard Capital Management increased its Palvella Therapeutics (PVLA) stake by 7.6% in Q2 2026, buying an estimated $4.43M and bringing the position to 513,794 shares worth $78.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1691.

Vanguard Capital Management first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Vanguard Capital Management held 513,794 shares of Palvella Therapeutics worth $78.5M as of Q2 2026.
  • Vanguard Capital Management bought 36,500 Palvella Therapeutics shares in Q2 2026, an estimated $4.43M.
  • Palvella Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1691 holding.
  • Vanguard Capital Management first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.